{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:04:13Z","timestamp":1790730253828,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejca.2023.03.024","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:37:52Z","timestamp":1679629072000},"page":"122-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-4909","authenticated-orcid":false,"given":"Alice","family":"Boil\u00e8ve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fodil-Cherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-1204","authenticated-orcid":false,"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.024_bib1","first-page":"1770","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018"},{"issue":"10","key":"10.1016\/j.ejca.2023.03.024_bib2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","article-title":"Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma","volume":"28","author":"Frizziero","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.024_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D: molecular landscape of lung neuroendocrine tumours","volume":"241","author":"Simbolo","year":"2017","journal-title":"J Pathol"},{"issue":"14","key":"10.1016\/j.ejca.2023.03.024_bib4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2023.03.024_bib5","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.03.024_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"7643","key":"10.1016\/j.ejca.2023.03.024_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2023.03.024_bib8","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.024_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13073-022-01083-1","article-title":"Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors","volume":"14","author":"M\u00e4kinen","year":"2022","journal-title":"Genome Med"},{"issue":"7","key":"10.1016\/j.ejca.2023.03.024_bib10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.024_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2729","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.03.024_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.ejca.2023.03.024_bib13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.03.024_bib14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","volume":"30","author":"Tr\u00e9dan","year":"2019","journal-title":"Ann Oncol"},{"issue":"7931","key":"10.1016\/j.ejca.2023.03.024_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","article-title":"Genomics to select treatment for patients with metastatic breast cancer","volume":"610","author":"Andre","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2023.03.024_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.03.024_bib17","first-page":"1239","article-title":"Copenhagen Prospective Personalized Oncology (CoPPO)-clinical utility of using molecular profiling to select patients to phase I trials","volume":"25","author":"Tuxen","year":"2019"},{"key":"10.1016\/j.ejca.2023.03.024_bib18","article-title":"Implementing the European society for medical oncology scale for clinical actionability of molecular targets in a comprehensive profiling program: impact on precision medicine oncology","volume":"6","author":"Martin-Romano","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.024_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.03.024_bib20","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2023.03.024_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.024_bib22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","article-title":"Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas","volume":"19","author":"Gilardi","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"10022","key":"10.1016\/j.ejca.2023.03.024_bib23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.024_bib24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/ERC-18-0332","article-title":"Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials","volume":"26","author":"Yao","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.024_bib25","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ejca.2023.03.024_bib26","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.03.024_bib27","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov"},{"issue":"7804","key":"10.1016\/j.ejca.2023.03.024_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejca.2023.03.024_bib29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","article-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","volume":"11","author":"Horak","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.024_bib30","first-page":"525","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.03.024_bib31","doi-asserted-by":"crossref","first-page":"L21","DOI":"10.1530\/ERC-16-0419","article-title":"Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases","volume":"24","author":"Karpathakis","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"22","key":"10.1016\/j.ejca.2023.03.024_bib32","article-title":"Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)","volume":"S0923\u20137534","author":"Bayle","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:13Z","timestamp":1760733613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":32,"alternative-id":["S0959804923001594"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}